Neoadjuvant Therapy for HER2 Positive Breast Cancer: Case Study

Breast cancer is the most common cancer among women worldwide.

- TDG NETWORK

According to the World Health Organization, in 2022, around 2.3 million women were diagnosed with this disease. About 15% to 20% of all breast cancer cases are HER2-positive (human epidermal growth factor receptor 2-positive). HER2-positive breast cancer is more aggressive and spreads faster than other types of breast cancer. HER2 is a protein crucial for cell growth, but in HER2-positive breast cancer, cancer cells have this protein in excess, causing them to multiply more aggressively than normal breast cells. This leads to poorer outcomes.

Dr. Mandeep Singh Malhotra says, "It is very important to give the right information to patients and their families for better outcomes. With the right treatment sequence, it is possible to offer better care to patients."

Treatment for HER2 Positive Breast Cancer

According to researchers from the European Society for Medical Oncology, it is essential to personalize the treatment of patients diagnosed with this type of breast cancer. Advances in targeted therapy have significantly improved prognosis. Neoadjuvant therapy, a treatment given before surgery, has become a crucial strategy in managing HER2-positive breast cancer.